FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Judith Wessels

Research Profile

Genes & Molecular Sequences

Single Nucleotide Polymorphism

Occupations

Pharmacogenetics

Chemicals & Drugs

Disorders

Physiology

Haplotypes

Living Beings

Concepts & Ideas

Procedures

Single-Blind Method

Co-author Network

Publications

TOP 3
Dyah A Perwitasari; Robert J H M van der Straaten; Judith A M Wessels; Hans Gelderblom; Mustofa Mustofa; Henk-Jan Guchelaar
Differences in 5-hydroxytryptamine-3B haplotype frequencies between Asians and Caucasians.
Jeffrey J W Verschuren; Judith A M Wessels; Moniek P M de Maat; Henk-Jan Guchelaar; Maarten L Simoons; Stella Trompet; J Wouter Jukema
A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?
Dyah A Perwitasari; Robert J H M van der Straaten; Judith A M Wessels; Renee F Baak-Pablo; Hans Gelderblom; Mohammad Hakimi; Mustofa Mustofa; Johann W R Nortier; Henk-Jan Guchelaar
Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Judith Wessels (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Dyah A Perwitasari; Robert J H M van der Straaten; Judith A M Wessels; Hans Gelderblom; Mustofa Mustofa; Henk-Jan Guchelaar
Differences in 5-hydroxytryptamine-3B haplotype frequencies between Asians and Caucasians.
The International journal of biological markers 2012;27(1):34-8.
2012: Jeffrey J W Verschuren; Judith A M Wessels; Moniek P M de Maat; Henk-Jan Guchelaar; Maarten L Simoons; Stella Trompet; J Wouter Jukema
A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?
European heart journal 2012;33(2):165-75.
2011: Dyah A Perwitasari; Robert J H M van der Straaten; Judith A M Wessels; Renee F Baak-Pablo; Hans Gelderblom; Mohammad Hakimi; Mustofa Mustofa; Johann W R Nortier; Henk-Jan Guchelaar
Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy.
Japanese journal of clinical oncology 2011;41(10):1168-76.
2011: Neeltje Steeghs; Tahar van der Straaten; Judith A M Wessels; Bernard Laffranchi; Mariangela Mariani; Ron H J Mathijssen; Silvia Comis; Anne-Joy de Graan; Maja J A de Jonge; Hans Gelderblom; Henk-Jan Guchelaar
Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib.
Investigational new drugs 2011;29(5):953-62.
2011: Frans L Opdam; Jesse J Swen; Judith A M Wessels; Hans Gelderblom
SNPs and haplotypes in DPYD and outcome of capecitabine--Letter.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(17):5833-4; author reply 5835-6.
2011: Rianne M F van Schie; Talitha I Verhoef; Judith A M Wessels; Anthonius de Boer; Saskia Le Cessie; Anke Hilse Maitland-van der Zee; Frits R Rosendaal; Tom Schalekamp; Felix J M van der Meer; Erik van Meegen
Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data.
European heart journal 2011;32(15):1909-17.
2011: Jesse J Swen; Willem J J Assendelft; Renée F Baak-Pablo; Henk-Jan Guchelaar; Judith A M Wessels
Genetic risk factors for type 2 diabetes mellitus and response to sulfonylurea treatment.
Pharmacogenetics and genomics 2011;21(8):461-8.
2011: Astrid A M van der Veldt; Karel Eechoute; Hans Gelderblom; Jourik Gietema; Henk-Jan Guchelaar; Nielka P H van Erp; Alfons J M van den Eertwegh; John B A G Haanen; Ron H J Mathijssen; Judith A M Wessels
Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(3):620-9.
2009: Thierry Dervieux; Henk-Jan Guchelaar; Jason H Moore; Nadia Penrod; Tahar van der Straaten; Judith A M Wessels; Joel M Kremer
Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis.
Pharmacogenetics and genomics 2009;19(12):935-44.
2009: Maurits E L Arbouw; Kris L L Movig; Toine C G Egberts; Petra J E Poels; Jeroen P P van Vugt; Judith A M Wessels; R J H M van der Straaten; Cees Neef; Henk-Jan Guchelaar
Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson's disease.
European journal of clinical pharmacology 2009;65(12):1245-51.
2009: Nielka P van Erp; Karel Eechoute; Astrid A van der Veldt; John B Haanen; An K L Reyners; Ron H J Mathijssen; Epie Boven; Tahar van der Straaten; Renée F Baak-Pablo; Judith A M Wessels; Henk-Jan Guchelaar; Hans Gelderblom
Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(26):4406-12.
2009: Wouter M Kooloos; Henk-Jan Guchelaar; Tom W J Huizinga; Judith A M Wessels
Comment on: Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate.
Rheumatology (Oxford, England) 2009;48(9):1176-7; author reply 1177.
2009: Wouter M Kooloos; Judith A M Wessels; Tahar van der Straaten; Tom W J Huizinga; Henk-Jan Guchelaar
Criteria for the selection of single nucleotide polymorphisms in pathway pharmacogenetics: TNF inhibitors as a case study.
Drug discovery today 2009;14(17-18):837-44.
2007: Judith A M Wessels; Sjoerd M van der Kooij; Saskia Le Cessie; Wietske Kievit; Pilar Barerra; Cornelia F Allaart; Tom W J Huizinga; Henk-Jan Guchelaar
A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis.
Arthritis and rheumatism 2007;56(6):1765-75.
2007: R J H M van der Straaten; Judith A M Wessels; Jeska K de Vries-Bouwstra; Yvonne P M Goekoop-Ruiterman; Cornelia F Allaart; Judith Bogaartz; Marco Tiller; Tom W J Huizinga; Henk-Jan Guchelaar
Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients.
Pharmacogenomics 2007;8(2):141-50.
2006: Joanna Wesoly; Judith A M Wessels; Henk-Jan Guchelaar; Tom W J Huizinga
Genetic markers of treatment response in rheumatoid arthritis.
Current rheumatology reports 2006;8(5):369-77.
2006: Judith A M Wessels; Wouter M Kooloos; Robert de Jonge; Jeska K de Vries-Bouwstra; Cornelia F Allaart; Annelies Linssen; Gerard Collee; Peter De Sonnaville; Jan Lindemans; Tom W J Huizinga; Henk-Jan Guchelaar
Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis.
Arthritis and rheumatism 2006;54(9):2830-9.
2006: Judith A M Wessels; Jeska K de Vries-Bouwstra; Bas Heijmans; P Eline Slagboom; Yvonne P M Goekoop-Ruiterman; Cornelia F Allaart; Pit J S M Kerstens; Derkjen van Zeben; Ferdinand C Breedveld; B A C Dijkmans; Tom W J Huizinga; Henk-Jan Guchelaar
Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes.
Arthritis and rheumatism 2006;54(4):1087-95.
2002: Umesh A Badrising; Marion L C Maat-Schieman; Michel D Ferrari; Aeilko H Zwinderman; Judith A M Wessels; Ferdinand C Breedveld; Pieter A Van Doorn; B G M van Engelen; Jessica E Hoogendijk; Chris J Höweler; Aeiko E de Jager; F G I Jennekens; Peter J Koehler; Marianne De Visser; Alain Viddeleer; Jan J Verschuuren; Axel R Wintzen
Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo.
Annals of neurology 2002;51(3):369-72.